Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1469042

	registered interest
	date	09/06/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Steroid Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if his Department will make recurrent oral corticosteroids prescriptions from primary care a trigger for referral to secondary or tertiary care for asthma patients.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	15243
	answer	answer is ministerial correction date of answer 07/07/2022 answer text <p>While the National Institute of Health and Care Excellence’s (NICE) guideline ‘Asthma: diagnosis, monitoring and chronic asthma management’ does not specifically make recommendations on oral corticosteroids, NICE is working with the British Thoracic Society and the Scottish Intercollegiate Guidelines Network to produce United Kingdom-wide guidance to update and replace this guideline. Evidence on pharmacological management, including the use of oral corticosteroids, will be reviewed during this process.</p><p>The 2022/23 Quality and Outcomes Framework incentivises general practitioners to assess asthma control through a questionnaire, which records of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan, to monitor potential over-prescribing. The Impact and Investment Fund currently contains two indicators which aim to improve the care of people with asthma, including recognising Primary Care Networks which reduce in the percentage of patients receiving six or more Short-Acting Beta Agonists (SABAs) prescriptions per year.</p><p>NICE’s guidelines for asthma and its guideline ‘Chronic obstructive pulmonary disease in over 16s: diagnosis and management’ recommend oral corticosteroids and alternatives. For adults with asthma, these include SABAs, leukotriene receptor antagonists and long-acting beta2 agonists. For chronic obstructive pulmonary disease (COPD), NICE recommends smoking cessation, SABAs and short-acting muscarinic antagonists, Theophylline tablets, oral mucolytic therapy, oral anti-oxidant therapy, oral anti-tussive therapy, oral prophylactic antibiotic therapy, long-term oxygen therapy, ambulatory oxygen therapy, short-burst oxygen therapy, non-invasive ventilation and pulmonary rehabilitation. NICE has also published technology appraisal guidance on biologics for those with severe asthma, such as Omalizumab for treating severe persistent allergic asthma.</p><p>No specific assessment has been made of the cost of caring for and treating adverse events in patients prescribed frequent or maintenance prescriptions of oral corticosteroids. However, in developing its guidelines, NICE has recommended a number of medicines for patients with severe asthma, such as mepolizumab, which considered the costs and benefits relating to a potential reduction in the use of corticosteroids.</p><p>NHS England and NHS Improvement’s Severe Asthma Collaborative is developing capacity in severe asthma centres to streamline patient pathways to biologic therapies and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.</p><p>The Royal College of General Practitioners’ guidance on long term condition recovery asks clinicians to consider all high-risk patients with COPD and asthma who have not received a review for more than 12 months and have been prescribed either three or more SABAs in the last 12 months; those aged five years old and over not on the asthma or COPD register who have received two or more courses of oral steroids in 12 months; and those on the asthma or COPD register to be prioritised for review.</p><p> </p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 15244 15245 15260 15263 question first answered 07/07/2022 16:26:15 answering member 4680 label Biography information for Gillian Keegan
	tabling member	4034 label Biography information for Yvonne Fovargue

1469043

	registered interest
	date	09/06/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Steroid Drugs: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to encourage primary care clinicians to monitor potential over-prescribing of oral corticosteroids.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	15244
	answer	answer is ministerial correction date of answer 07/07/2022 answer text <p>While the National Institute of Health and Care Excellence’s (NICE) guideline ‘Asthma: diagnosis, monitoring and chronic asthma management’ does not specifically make recommendations on oral corticosteroids, NICE is working with the British Thoracic Society and the Scottish Intercollegiate Guidelines Network to produce United Kingdom-wide guidance to update and replace this guideline. Evidence on pharmacological management, including the use of oral corticosteroids, will be reviewed during this process.</p><p>The 2022/23 Quality and Outcomes Framework incentivises general practitioners to assess asthma control through a questionnaire, which records of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan, to monitor potential over-prescribing. The Impact and Investment Fund currently contains two indicators which aim to improve the care of people with asthma, including recognising Primary Care Networks which reduce in the percentage of patients receiving six or more Short-Acting Beta Agonists (SABAs) prescriptions per year.</p><p>NICE’s guidelines for asthma and its guideline ‘Chronic obstructive pulmonary disease in over 16s: diagnosis and management’ recommend oral corticosteroids and alternatives. For adults with asthma, these include SABAs, leukotriene receptor antagonists and long-acting beta2 agonists. For chronic obstructive pulmonary disease (COPD), NICE recommends smoking cessation, SABAs and short-acting muscarinic antagonists, Theophylline tablets, oral mucolytic therapy, oral anti-oxidant therapy, oral anti-tussive therapy, oral prophylactic antibiotic therapy, long-term oxygen therapy, ambulatory oxygen therapy, short-burst oxygen therapy, non-invasive ventilation and pulmonary rehabilitation. NICE has also published technology appraisal guidance on biologics for those with severe asthma, such as Omalizumab for treating severe persistent allergic asthma.</p><p>No specific assessment has been made of the cost of caring for and treating adverse events in patients prescribed frequent or maintenance prescriptions of oral corticosteroids. However, in developing its guidelines, NICE has recommended a number of medicines for patients with severe asthma, such as mepolizumab, which considered the costs and benefits relating to a potential reduction in the use of corticosteroids.</p><p>NHS England and NHS Improvement’s Severe Asthma Collaborative is developing capacity in severe asthma centres to streamline patient pathways to biologic therapies and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.</p><p>The Royal College of General Practitioners’ guidance on long term condition recovery asks clinicians to consider all high-risk patients with COPD and asthma who have not received a review for more than 12 months and have been prescribed either three or more SABAs in the last 12 months; those aged five years old and over not on the asthma or COPD register who have received two or more courses of oral steroids in 12 months; and those on the asthma or COPD register to be prioritised for review.</p><p> </p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 15243 15245 15260 15263 question first answered 07/07/2022 16:26:15 answering member 4680 label Biography information for Gillian Keegan
	tabling member	4034 label Biography information for Yvonne Fovargue

1469044

	registered interest
	date	09/06/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma and Chronic Obstructive Pulmonary Disease: Steroid Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what alternatives to oral corticosteroids treatment are available for asthma and COPD patients.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	15245
	answer	answer is ministerial correction date of answer 07/07/2022 answer text <p>While the National Institute of Health and Care Excellence’s (NICE) guideline ‘Asthma: diagnosis, monitoring and chronic asthma management’ does not specifically make recommendations on oral corticosteroids, NICE is working with the British Thoracic Society and the Scottish Intercollegiate Guidelines Network to produce United Kingdom-wide guidance to update and replace this guideline. Evidence on pharmacological management, including the use of oral corticosteroids, will be reviewed during this process.</p><p>The 2022/23 Quality and Outcomes Framework incentivises general practitioners to assess asthma control through a questionnaire, which records of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan, to monitor potential over-prescribing. The Impact and Investment Fund currently contains two indicators which aim to improve the care of people with asthma, including recognising Primary Care Networks which reduce in the percentage of patients receiving six or more Short-Acting Beta Agonists (SABAs) prescriptions per year.</p><p>NICE’s guidelines for asthma and its guideline ‘Chronic obstructive pulmonary disease in over 16s: diagnosis and management’ recommend oral corticosteroids and alternatives. For adults with asthma, these include SABAs, leukotriene receptor antagonists and long-acting beta2 agonists. For chronic obstructive pulmonary disease (COPD), NICE recommends smoking cessation, SABAs and short-acting muscarinic antagonists, Theophylline tablets, oral mucolytic therapy, oral anti-oxidant therapy, oral anti-tussive therapy, oral prophylactic antibiotic therapy, long-term oxygen therapy, ambulatory oxygen therapy, short-burst oxygen therapy, non-invasive ventilation and pulmonary rehabilitation. NICE has also published technology appraisal guidance on biologics for those with severe asthma, such as Omalizumab for treating severe persistent allergic asthma.</p><p>No specific assessment has been made of the cost of caring for and treating adverse events in patients prescribed frequent or maintenance prescriptions of oral corticosteroids. However, in developing its guidelines, NICE has recommended a number of medicines for patients with severe asthma, such as mepolizumab, which considered the costs and benefits relating to a potential reduction in the use of corticosteroids.</p><p>NHS England and NHS Improvement’s Severe Asthma Collaborative is developing capacity in severe asthma centres to streamline patient pathways to biologic therapies and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.</p><p>The Royal College of General Practitioners’ guidance on long term condition recovery asks clinicians to consider all high-risk patients with COPD and asthma who have not received a review for more than 12 months and have been prescribed either three or more SABAs in the last 12 months; those aged five years old and over not on the asthma or COPD register who have received two or more courses of oral steroids in 12 months; and those on the asthma or COPD register to be prioritised for review.</p><p> </p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 15243 15244 15260 15263 question first answered 07/07/2022 16:26:15 answering member 4680 label Biography information for Gillian Keegan
	tabling member	4034 label Biography information for Yvonne Fovargue

1237500

	registered interest
	date	24/09/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Internet: Fraud
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what plans she has to tackle user-generated fraudulent and scam content on online platforms.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	95068
	answer	answer is ministerial correction date of answer 01/10/2020 answer text <p>We know that people are spending more time online during this period and this can put them at greater risk of experiencing online harm. We have been working closely with technology companies, civil society and academia to understand and respond to the risks presented during this period.</p><p>The department is committed to tackling all forms of crime, including those that exploit technology and the internet. We are considering all routes to ensure law enforcement have the tools they need to go after these criminals and to protect the vulnerable.</p><p>HMG published new guidance on April 23rd to help all users to stay safe online during the coronavirus outbreak. It includes detailed advice on protecting personal data, cyber security and disinformation. It also provides additional guidance for parents on online safety issues affecting children such as child sexual abuse, exposure to age-inappropriate content and cyberbullying.</p><p>This Government is committed to delivering legislation to tackle online harms. This will introduce a statutory duty of care on companies to take steps to protect their users from harm, including child sexual exploitation and abuse. We are currently working swiftly to prepare a full Government response, which we will publish later this year. This will include more detailed proposals on online harms regulation and will be released alongside interim voluntary codes of practice on tackling online terrorist and child sexual exploitation and abuse content and activity. We will follow the full Government response by introducing Online Harms legislation.</p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire question first answered 01/10/2020 16:32:37 answering member 1530 label Biography information for James Brokenshire
	tabling member	4034 label Biography information for Yvonne Fovargue

1237501

	registered interest
	date	24/09/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Internet: Fraud
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what estimate she has made of (a) the volume of user-generated fraudulent and scam content posted on online platforms and (b) the harm that content has caused to victims of that fraud.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	95069
	answer	answer is ministerial correction date of answer 01/10/2020 answer text <p>We know that people are spending more time online during this period and this can put them at greater risk of experiencing online harm. We have been working closely with technology companies, civil society and academia to understand and respond to the risks presented during this period.</p><p>The department is committed to tackling all forms of crime, including those that exploit technology and the internet. We are considering all routes to ensure law enforcement have the tools they need to go after these criminals and to protect the vulnerable.</p><p>HMG published new guidance on April 23rd to help all users to stay safe online during the coronavirus outbreak. It includes detailed advice on protecting personal data, cyber security and disinformation. It also provides additional guidance for parents on online safety issues affecting children such as child sexual abuse, exposure to age-inappropriate content and cyberbullying.</p><p>This Government is committed to delivering legislation to tackle online harms. This will introduce a statutory duty of care on companies to take steps to protect their users from harm, including child sexual exploitation and abuse. We are currently working swiftly to prepare a full Government response, which we will publish later this year. This will include more detailed proposals on online harms regulation and will be released alongside interim voluntary codes of practice on tackling online terrorist and child sexual exploitation and abuse content and activity. We will follow the full Government response by introducing Online Harms legislation in this session.</p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire question first answered 01/10/2020 17:39:43 answering member 1530 label Biography information for James Brokenshire
	tabling member	4034 label Biography information for Yvonne Fovargue

1491423

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Obstructive Pulmonary Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has plans to include incentives within the Quality and Outcomes Framework or Investment and Impact Fund to help ensure that chronic obstructive pulmonary disease (COPD) patients receive a proactive review of their care after a prescription of oral corticosteroid for a COPD exacerbation.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41995
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>We have no specific plans to do so. However, the Quality and Outcomes Framework and the Investment and Impact Fund are reviewed to ensure alignment with the latest clinical guidance and best practice.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 10:38:51 answering member 3992 label Biography information for James Morris
	tabling member	4034 label Biography information for Yvonne Fovargue

1584997

	registered interest
	date	07/02/2023
	answering body	Department for Business and Trade
	answering dept id	214
	answering dept short name	Business and Trade
	answering dept sort name	Business and Trade
	hansard heading	Productivity: Insomnia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business and Trade, if she will make an assessment of the impact of insomnia on UK productivity.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	141451
	answer	answer is ministerial correction date of answer 15/02/2023 answer text <p>We have no plans to make an assessment of the impact on insomnia on UK productivity.</p> answering member constituency Wealden answering member printed Ms Nusrat Ghani question first answered 15/02/2023 15:31:43 answering member 4460 label Biography information for Ms Nusrat Ghani
	tabling member	4034 label Biography information for Yvonne Fovargue

1546153

	registered interest
	date	28/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Public Consultation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his planned timetable is for the publication of responses to the consultation entitled Advancing our health: prevention in the 2020s, published on 22 July 2019.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	97622
	answer	answer is ministerial correction date of answer 06/12/2022 answer text <p>We have no current plans to publish a summary of the responses to the consultation ‘Advancing our health: prevention in the 2020s’ and there are no plans to publish next steps.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 97624 question first answered 06/12/2022 15:53:43 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

1546156

	registered interest
	date	28/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Public Consultation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his planned timetable is for the publication of next steps following the consultation entitled Advancing our health: prevention in the 2020s, published on 22 July 2019.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	97624
	answer	answer is ministerial correction date of answer 06/12/2022 answer text <p>We have no current plans to publish a summary of the responses to the consultation ‘Advancing our health: prevention in the 2020s’ and there are no plans to publish next steps.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 97622 question first answered 06/12/2022 15:53:43 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

349216

	registered interest
	date	08/06/2015
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Railways: Franchises
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, what recent assessment he has made of the effectiveness of the rail franchise system.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	900260
	answer	answer is ministerial correction date of answer 11/06/2015 answer text <p>We continuously monitor a range of indicators, including performance figures and passenger satisfaction. Rail use is at its highest level since the 1920s: 1.65 billion passenger journeys were made in Great Britain on franchised passenger trains in 2014-15. The number of journeys made on the rail network has more than doubled since the introduction of the franchise system.</p> answering member constituency Devizes answering member printed Claire Perry question first answered 11/06/2015 13:26:58 answering member 3974 label Biography information for Claire Perry
	tabling member	4034 label Biography information for Yvonne Fovargue